JFJulie Falardeau

Julie Falardeau

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Julie Falardeau has a total of 40 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Artificial Intelligence in Neuro-Ophthalmology for Optic Disc Pathologies and Neurodegenerative Disease

    by Abhimanyu S Ahuja, Alfredo A Paredes Iii, Mallory Ls Eisel, Cole Miller, Nina Truong, Julie Falardeau

    Artificial intelligence (AI) is rapidly reshaping neuro-ophthalmic care by extracting clinically significant information from imaging, biomarkers, and patient-level clinical data. We review recent advances across neurodegenerative disease detection using retinal biomarkers, automated recognition of optic disc swelling and its mimics, glaucoma screening and quantification, and classification of hereditary optic neuropathies. Using fundus photography and optical coherence tomography (OCT), contemporary machine learning (ML) systems, including deep learning as well as other supervised learning models, report strong discrimination for papilledema versus pseudopapilledema, non-arteritic anterior ischemic optic neuropathy (NAION) against similar presenting entities, and glaucomatous damage including indirect estimation of retinal nerve fiber layer (RNFL) thickness. Early work also suggests that retinal features can aid detection of mild cognitive impairment (MCI) and major neurocognitive disease. However, despite promising results, most studies remain retrospective and single-center, while focusing on imaging-only, limiting generalizability and clinical interpretability. Therefore a variety of challenges related to dataset heterogeneity, overfitting, limited external validation, and the gap between high diagnostic accuracy and practical clinical utility remain unresolved. Future prospective, multicenter evaluations focusing on integrating multimodal clinical data through explainable AI systems are necessary to improve diagnostic consistency, shorten time to care, and expand access for underserved populations.


  • Risk of Stroke Recurrence Following Isolated Retinal Artery Occlusion Versus Minor Stroke or Transient Ischemic Attack

    by Huanwen Chen, Marco Colasurdo, Julie Falardeau, Matthew K. McIntyre, Ajay Malhotra, Thanh N. Nguyen, James E. Siegler, Dheeraj Gandhi

    BACKGROUND: Retinal artery occlusion (RAO) is a form of ischemic stroke per the American Heart Association, yet high-level evidence guiding management and prognostication is limited. The risk of future cerebral infarction following nonarteritic isolated RAO (iRAO; without concomitant cerebral infarction) is unclear. This study compares the risk of stroke recurrence following iRAO versus nondisabling ischemic cerebrovascular events (NICEs), including transient ischemic attacks and minor ischemic strokes. METHODS: This was a retrospective cohort study using the 2016 to 2022 Nationwide Readmissions Database in the United States. Adults hospitalized primarily for RAO or NICE were included. Patients who were functionally dependent at discharge or had moderate to severe stroke (National Institutes of Health Stroke Scale score >4), arteritis or vasculitis, or RAO and concomitant cerebral infarction were excluded from the primary analysis. Two-to-one propensity score matching was performed to balance baseline characteristics between cohorts. The primary outcome was subsequent cerebral infarction within 300 days. Cox regression models and multivariable adjustments were used to estimate hazard ratios. RESULTS: A total of 1 673 145 patients hospitalized for nondisabling stroke, transient ischemic attack, or RAO were identified; 17 388 (1.0%) had RAO, of whom 4507 (25.9%) had concomitant cerebral infarction and were excluded for primary analyses. After applying additional exclusion criteria and propensity score matching, 11 185 patients with nonarteritic iRAO and 22 757 patients with NICE remained. Patients with iRAO had a significantly lower risk of subsequent cerebral infarction (hazard ratio, 0.26 [95% CI, 0.20–0.35]; P P <0.001 for all). CONCLUSIONS: Nonarteritic iRAO events were associated with significantly lower risks of subsequent cerebral infarction compared with NICE. These findings suggest that iRAO events are not equivalent to ischemic cerebrovascular events in terms of risk of subsequent stroke. Further studies are needed to optimize secondary stroke prevention strategies tailored to nonarteritic iRAOs.


  • Open Access

    Optical coherence tomographic angiography detects retinal vascular changes associated with pituitary adenoma

    by Ping Wei, Julie Falardeau, Aiyin Chen, Jie Wang, Liang Liu, Yali Jia, David Huang


  • New Options (or not) for Treatment of Idiopathic Intracranial Hypertension

    by Julie Falardeau

    Purpose of review Idiopathic intracranial hypertension (IIH) is a disorder primarily affecting obese women of childbearing age and, if left untreated, can lead to irreversible vision loss. No consensus exists on the best management strategy for IIH. Weight loss is advocated and few useful medical options exist. There is an unmet need to discover new treatment options for this increasingly prevalent condition. This article reviews the recent advances and research on the treatment of IIH. Recent findings Venous sinus stenting (VSS) is now performed in many experienced centers, and there is growing interest in bariatric surgery as a treatment modality. Newly approved anti-obesity drugs are showing effectiveness in weight loss, and novel targeted disease-modifying IIH therapies are being explored. Summary Further evaluation of these novel therapeutic strategies as well as studies exploring the use of anti-obesity drugs in IIH is needed. While VSS is gaining popularity due to its efficacy and low complication rate, there is insufficient evidence to support any surgical procedure over another. Bariatric surgery is appealing for patients with non-sight-threatening IIH and needs to be further explored.

  • Open Access

    Oral lipoic acid as a treatment for acute optic neuritis: a blinded, placebo controlled randomized trial

    by Julie Falardeau, Allison Fryman, Rohan Wanchu, Gail H Marracci, Michele Mass, Lindsey Wooliscroft, Dennis N Bourdette, Charles F Murchison, William L Hills, Vijayshree Yadav

    Background: Lipoic acid, an antioxidant, has beneficial effects in experimental acute optic neuritis and autoimmune encephalomyelitis. Optical coherence tomography can detect retinal nerve fiber layer thinning, representing axonal degeneration, approximately 3–6 months after acute optic neuritis. Objective: To determine whether lipoic acid is neuroprotective in acute optic neuritis. Methods: A single-center, double-blind, randomized, placebo controlled, 24-week trial. Intervention included 6 weeks of once daily lipoic acid (1200 mg) or placebo within 14 days of acute optic neuritis diagnosis. The primary outcome was the mean difference in affected eye retinal nerve fiber layer (RNFL) thickness from baseline to 24 weeks. Results: We enrolled 31 subjects (placebo n=16; lipoic acid n=15; average age 38.6 years (standard deviation (SD) 10.3)). Affected eye mean global RNFL thickness (µm) in the lipoic acid group decreased from 108.47 (SD 26.11) at baseline to 79.31 (SD 19.26) at 24 weeks. The affected eye RNFL in the placebo group decreased from 103.67 (SD 18.04) at baseline to 84.43 (SD 20.94) at 24 weeks. Unaffected eye RNFL thickness did not significantly change in either group over 24 weeks. Conclusion: Six weeks of oral lipoic acid supplementation after acute optic neuritis is safe and well tolerated; however, because of insufficient recruitment, we could not conclude that lipoic acid treatment was neuroprotective in acute optic neuritis.


  • The unfaithful neuritis

    by Luca De Simone, Francesco Pellegrini, Daniele Cirone, Luca Cimino, Julie Falardeau


  • Atypical Optic Neuritis

    by Eric D. Gaier, Katherine Boudreault, Joseph F. Rizzo, Julie Falardeau, Dean M. Cestari


  • The Use of Acetazolamide During Pregnancy in Intracranial Hypertension Patients

    by Julie Falardeau, Brenna M. Lobb, Sara Golden, Steven D. Bs Maxfield, Emanuel Tanne

    Background: Acetazolamide is the mainstay of medical therapy for idiopathic intracranial hypertension (IIH). Its use in pregnant women has not been recommended because of reported teratogenic effects in rodents and rabbits. However, the safety of acetazolamide use during human pregnancy remains unclear. We report the pregnancy and offspring outcomes in women with intracranial hypertension (IH) treated with acetazolamide during pregnancy. Methods: Data were collected through questionnaires sent to patients with IH and their physicians. The questionnaires focused on IH diagnosis, obstetric history and outcomes, and pediatric outcomes. Results: A total of 101 women with IH were consented (total of 158 pregnancies) and acetazolamide usage before 13 weeks of gestation was reported in 50 pregnancies. The risk of spontaneous abortion was similar to the control group and no major complication was identified in the offspring of women treated with acetazolamide. Conclusion: There is no convincing evidence for an adverse effect for acetazolamide use in human pregnancy, even when prescribed prior to the 13th week of gestation. While the liberal use of acetazolamide should be avoided during pregnancy, this medication should remain a treatment option in pregnant women when clinically indicated.